Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. J Bone Miner Res. 2022 Aug 14;6(9):e10665. doi: 10.1002/jbm4.10665

Gilsenan AW, Brainsky A, Colilla S. Applying CIRS-BRAT framework in a regulatory setting: updated benefit risk assessment for fibrinogen concentrate in the setting of complex cardiac surgery. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):964. doi: 10.1002/pds.4864

Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590

Kellier N, Krohn K, Gilsenan AW, Harris DH, Andrews EB, Massica D. Forteo voluntary patient registry: 3-Year progress on a prospective osteosarcoma surveillance study. Poster presented at the American Society for Bone and Mineral Research Annual Meeting; October 6, 2013.

Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324